• In late April 2026, Johnson & Johnson reported strong first‑quarter results with revenue of US$24.06 billion, raised its full‑year sales outlook to US$100.30–US$101.30 billion, increased its quarterly dividend to US$1.34 per share, and advanced key therapies including IMAAVY (nipocalimab) receiving FDA Priority Review in warm autoimmune hemolytic anemia and CAPLYTA (lumateperone) gaining an expanded label for preventing schizophrenia relapse.
• These moves highlight Johnson & Johnson’s effort to offset patent and legal pressures by deepening its portfolio in high‑need areas like rare autoimmune disease and neuropsychiatry, while also signaling confidence through higher guidance and a continued pattern of dividend growth.
• We’ll now examine how FDA Priority Review for IMAAVY in warm autoimmune hemolytic anemia reshapes Johnson & Johnson’s investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson today, you need to believe it can replace pressure from maturing blockbusters and legal overhangs with a broad, innovation‑led drug and MedTech portfolio. The latest IMAAVY and CAPLYTA updates support that thesis by adding depth in immunology and neuroscience, but they do not remove near term uncertainty around talc litigation or the impact of STELARA biosimilars on revenue and margins.

Among the recent announcements, the FDA Priority Review for IMAAVY in warm autoimmune hemolytic anemia looks most relevant. It reinforces Johnson & Johnson’s push into rare autoimmune diseases where there are currently no FDA approved therapies, and it may strengthen the case that newer assets can partially counterbalance loss of exclusivity and help support the company’s raised 2026 revenue outlook of US$100.30–US$101.30 billion.

But while product wins grab headlines, investors should also be aware of the unresolved talc litigation risk and how it could...

Johnson & Johnson's narrative projects $116.4 billion revenue and $26.9 billion earnings by 2029. This requires 6.5% yearly revenue growth and about a $5.9 billion earnings increase from $21.0 billion today.

Uncover how Johnson & Johnson's forecasts yield a $252.42 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some analysts were already far more optimistic, assuming revenue could reach about US$115.7 billion by 2029, so against that backdrop the recent IMAAVY news might either reinforce or challenge your view of how concentrated blockbuster risks really are.

Explore 12 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 66% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.